Header Logo

The efficacy of routine use of recombinant human bone morphogenetic protein-2 in occipitocervical and atlantoaxial fusions of the pediatric spine: a minimum of 12 months' follow-up with computed tomography.

Sayama C, Hadley C, Monaco GN, Sen A, Brayton A, BriceƱo V, Tran BH, Ryan SL, Luerssen TG, Fulkerson D, Jea A. The efficacy of routine use of recombinant human bone morphogenetic protein-2 in occipitocervical and atlantoaxial fusions of the pediatric spine: a minimum of 12 months' follow-up with computed tomography. J Neurosurg Pediatr. 2015 Jul; 16(1):14-20.

View in: PubMed